Free Trial

BioNTech Say Ph.3 Trial Data Shows High Efficacy Of Booster

POLITICAL RISK

=Pfizer/BioNTech release press statement saying that phase three trials of using their COVID-19 as a third-dose booster shows high efficacy in combatting coronavirus.

  • BioNTech tweets: "95.6% relative vaccine efficacy against #Covid19 after a booster shot with our #mRNA vaccine, during a period when Delta was the prevalent strain. These are the first efficacy results from any randomized, controlled vaccine booster trial." Link to press release here.
  • The rollout of booster doses around the world remains sporadic, with Israel surging ahead but previous world leaders - such as the UK - barely starting their booster programme.

Chart 1. COVID-19 Booster Doses Administered Per 100 Population

Source: ourworldindata.com, MNI

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.